2015
High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes
Abstract: Cell-based high-content screening (HCS) assays have become an increasingly attractive alternative to traditional in vitro and in vivo testing in pharmaceutical drug development and toxicological safety assessment. The time- and cost-effectiveness of HCS assays, combined with the organotypic nature of human induced pluripotent stem cell (iPSC)-derived cells, open new opportunities to employ physiologically relevant in vitro model systems to improve screening for potential chemical hazards. In this study, we use…
Search citation statements
Paper Sections
Select...
194
17
14
11
Citation Types
4
139
0
0
Year Published
2016
2026
Publication Types
Select...
109
102
7
1
Relationship
19
200
Authors
Journals
Cited by 219 publications
(143 citation statements)
References 35 publications
4
139
0
0
“…Our second key finding was that the degree of inter-individual variability in responses to treatment depends reproducibly on chemical and phenotypic endpoints. In cardiomyocytes derived from the standard commercial iCell cardiomyocyte product offered by Cellular Dynamics International (individual 1434), the results for our selected reference compounds are in excellent agreement with previous reports (Grimm et al, 2015;Sirenko et al, 2013aSirenko et al, ,b, 2017. Population-level differences in drug response are evident and the degree of interindividual variability in responses differ depending on chemical and endpoint.…”
Section: Discussionsupporting
confidence: 91%
“…Our second key finding was that the degree of inter-individual variability in responses to treatment depends reproducibly on chemical and phenotypic endpoints. In cardiomyocytes derived from the standard commercial iCell cardiomyocyte product offered by Cellular Dynamics International (individual 1434), the results for our selected reference compounds are in excellent agreement with previous reports (Grimm et al, 2015;Sirenko et al, 2013aSirenko et al, ,b, 2017. Population-level differences in drug response are evident and the degree of interindividual variability in responses differ depending on chemical and endpoint.…”
Section: Discussionsupporting
confidence: 91%
“…Our second key finding was that the degree of inter-individual variability in responses to treatment depends reproducibly on chemical and phenotypic endpoints. In cardiomyocytes derived from the standard commercial iCell cardiomyocyte product offered by Cellular Dynamics International (individual 1434), the results for our selected reference compounds are in excellent agreement with previous reports (Grimm et al, 2015;Sirenko et al, 2013aSirenko et al, ,b, 2017. Population-level differences in drug response are evident and the degree of inter-individual variability in responses differs depending on chemical and endpoint.…”
Section: Discussionsupporting
confidence: 91%
“…In cardiomyocytes derived from the standard commercial iCell cardiomyocyte product offered by Cellular Dynamics International (individual 1434), the results for our selected reference compounds are in excellent agreement with previous reports (Grimm et al, 2015; Sirenko et al, 2013a,b, 2017). Population-level differences in drug response are evident and the degree of inter-individual variability in responses differ depending on chemical and endpoint.…”
Section: Discussionsupporting
confidence: 90%
